Skip to main content

Free Post Earnings Research Report: BioPharmX’s Adjusted EPS Beat Expectations

LONDON, UK / ACCESSWIRE / January 09, 2018 / Active-Investors.com has just released a free earnings report on BioPharmX Corp. (NYSE: BPMX). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BPMX. The Company posted its financial results for the third quarter fiscal 2018, on December 07, 2017. The specialty pharmaceutical Company's adjusted diluted earnings per share (EPS) surpassed analysts' expectations. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, BioPharmX most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=BPMX

Earnings Highlights and Summary

For three months ended October 31, 2017, BioPharmX's revenues decreased 45.5% to $18,000 from $33,000 in Q3 FY17. The Company's revenues were below analysts' expectations of $20,000.

In the first nine months of 2017, the Company's revenue decreased % to $54,000 from $85,000 in the same period last year.

For the reported quarter, the Company's gross profit increased 100% to $10,000 from $5,000 in Q3 FY17. During Q3 FY18, BioPharmX's gross margin increased 4030 basis points to 55.5% of revenue from 15.2% of revenue in Q3 FY17.

In the first nine months of 2017, the Company's gross profit increased to $26,000 from $20,000 in the same period last year.

For the reported quarter, the Company's operating expenses decreased 10.1% to $3.75 million from $4.17 million in Q3 FY17. The decrease was due to lower spending for the company's acne drug clinical trials.

For the reported quarter, the Company's operating loss was $3.74 million compared to operating loss of $4.17 million in Q3 FY17.

In the first nine months of 2017, the Company's operating loss was $13.04 million compared to operating loss of $13.66 million in the same period last year.

During Q3 FY18, BioPharmX's earnings before tax (EBT) was negative $3.71 million compared to negative $3.88 million in the same period last year.

For the reported quarter, BioPharmX's net loss was $3.71 million compared to net loss of $3.88 million in Q3 FY17. During Q3 FY18, the Company's diluted EPS was negative $0.05 compared to negative $0.12 in the same period last year. For the reported quarter, BioPharmX's adjusted net loss was $3.27 million compared to adjusted net loss of $3.86 million in Q3 FY17. Adjusted net loss excluded stock-based compensation expense, expense related to the modification of warrants, the impact of changes in the fair value of the warrant liability and amortization of purchased intangible assets. During Q3 FY18, the Company's adjusted diluted was negative $0.04 compared to negative $0.12 in the same period last year. Adjusted diluted EPS surpassed analysts' expectations of negative $0.05.

In the first nine months of 2017, the Company's net loss was $12.85 million compared to net loss of $13.37 million in the same period last year. In the first nine months of 2017, the Company's diluted EPS was negative $0.17 compared to negative $0.47 in the same period last year.

Balance Sheet

As on October 31, 2017, BioPharmX's cash and cash equivalents decreased 75.7% to $1.58 million from $6.50 million on January 31, 2017.

For the reported quarter, the Company's net accounts receivable increased 100% to $8,000 from $4,000 in Q4 FY17. For the reported quarter, the Company's accounts payable decreased 21.2% to $2.01 million from $2.55 million in Q4 FY17.

In the first nine months of 2017, the Company's net cash provided by operating activities was negative $41,000 compared to negative $20,000 in the same period last year.

Stock Performance Snapshot

January 08, 2018 - At Monday's closing bell, BioPharmX's stock climbed 1.07%, ending the trading session at $0.11.

Volume traded for the day: 6.38 million shares, which was above the 3-month average volume of 2.48 million shares.

Stock performance in the last month – up 2.26%; and year-to-date – up 2.54%

After yesterday's close, BioPharmX's market cap was at $14.63 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.